Hercules, CA — November 5, 2014 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of two new NGC Medium-Pressure Chromatography Systems, the NGC Discover™ and NGC™ Discover Pro Systems. The automation capabilities of both systems make them ideal for advanced purification applications such as method optimization and multi-step and tandem protein purification.
Bio-Rad optimized the Discover and Discover Pro Systems for pharmaceutical environments. These systems are available with a 10 ml/min pump module or with the recently released NGC 100 ml/min pump module, which enables flow rates up to 200 ml/min when used in combination with a mixer module. The Discover Systems further increase throughput by being able to load multiple samples and run up to 15 columns sequentially. In addition, the Discover Pro System can collect 12 large-volume fractions via its outlet valve. These higher flow rates and throughput capabilities — all under software control for maximum automation — will enable pharmaceutical researchers to maximize efficiency and productivity in the lab.
The Discover Systems’ best feature, however, may be their ease of use, a hallmark of the NGC family of chromatography instruments.
“Over the past 18 months, researchers have embraced NGC Systems due to their straightforward operation that allows even chromatography novices to get up to speed in only one or two runs,” said Kamni Vijay, Bio-Rad marketing director, Protein Function Division, Life Science Group. “By reimagining chromatography instrumentation from the ground up, we’ve created a system that’s an asset in making important scientific discoveries.”
All NGC Systems feature the same modular design with interchangeable plug-and-play modules that allow researchers to scale the system according to their throughput needs.
Other benefits of the NGC Chromatography System family include:
- Faster setup — the Point-to-Plumb™ feature offers step-by-step LED-guided plumbing of the system and quicker instrument setup
- Automated methods and analysis — ChromLab™ Software provides method templates that meet any purification need and it reduces tedious analysis with time-saving features such as single-click peak integration and the ability to stack and overlay chromatograms
- Robust performance and regulatory compliance — all systems can be operated in compliance with 21CFR Part 11 regulations using ChromLab Software Security Edition. System-level IQ/OQ validation and rigorous testing ensure that all systems live up to the high-throughput demands of a pharmaceutical environment
For more information about Bio-Rad’s suite of NGC Chromatography Systems, please visit www.bio-rad.com/NGCpr.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of products for life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and industry customers through its global network of operations. The company employs approximately 7,800 people worldwide and had revenues exceeding $2.1 billion in 2013. Visit us at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact: